Molecular Targets & Therapeutics

Dr. Reid Alderson from the Institute of Structural Biology and the Institute of Computational Biology at Helmholtz Munich has received a Starting Grant from the European Research Council (ERC). Through the Protein-DANCE project, he will develop a new…

Medical diagnostic systems using ai to analyze patient data

What if analysing thousands of microscopic signals could be done in minutes rather than hours? Researchers at Helmholtz Munich have developed SpotMAX, a new AI-powered open-source framework that automates the detection and quantification of…

The CureGPX4 Foundation has named Prof. Marcus Conrad, Director of the Institute of Metabolism and Cell Death at Helmholtz Munich, as the first recipient of the Raghav Prize for Rare Disease and Citizen Science. The prize recognizes his research into…

Microscopic view of glioblastoma tumor cells

Helmholtz Munich, together with the University of Münster and ITM Isotope Technologies Munich SE (ITM), has reported updated preliminary results from a Phase 1 clinical trial evaluating ITM-31, a targeted radiotherapy for glioblastoma. The treatment…

Prof. Marcus Conrad has been elected a member of the German National Academy of Sciences Leopoldina. With this prestigious scientific honor, the Academy recognizes his outstanding contributions to the study of regulated cell death and its…